Livro
aTesamorelin (Egrifta) is indicated for the treatment of excess visceral adipose tissue (VAT), as assessed by waist circumference ≥ 95 cm for males and ≥ 94 cm for females, and confirmed by a VAT level > 130 cm2 by computed tomography (CT) scan
National Library of Medicine (NCBI); Linguagem: Português
Referência(s)